 | This article needs additional citations for verification. Please help improve this article by adding citations to reliable sources. Unsourced material may be challenged and removed. Find sources: "Tercica" – news · newspapers · books · scholar · JSTOR (July 2012) (Learn how and when to remove this message) |
| This article relies largely or entirely on a single source. Relevant discussion may be found on the talk page. Please help improve this article by introducing citations to additional sources. Find sources: "Tercica" – news · newspapers · books · scholar · JSTOR (November 2019) |
| Industry | Health care |
|---|---|
| Defunct | 2008 (2008) |
| Fate | Acquired by Ipsen Group |
| Successor | Ipsen Biopharmaceuticals, Inc. |
| Headquarters | Brisbane, California, United States |
Tercica, Inc., was a biopharmaceutical company based in Brisbane, California, United States. It developed Increlex (mecasermin injection), also known as recombinant human Insulin-like Growth Factor-1 (rhIGF-1). Tercica applied to the Food and Drug Administration (FDA) for approval of Increlex as a long-term therapy for growth failure in children with severe primary IGF-1 deficiency (Primary IGFD), which is characterized by growth failure, and as a treatment for children with growth hormone (GH) gene deletion who have developed neutralizing antibodies to growth hormone.
Tercica licensed rights to develop, manufacture, and market Increlex from Genentech, Inc. Increlex conducted Phase III clinical trials to evaluate the safety and efficacy of Increlex in children with Primary IGFD.
In 2007, a case between Insmed and Tercica was settled when the jury found that Insmed infringed patents licensed to Tercica for Increlex. In the settlement, Insmed agreed to stop selling Iplex in the United States as a treatment for growth deficiencies and to withdraw an application to have the drug approved for such use in Europe.
In 2008, the Ipsen Group acquired Tercica and changed its name to Ipsen Biopharmaceuticals, Inc.
See also
References
- Pollack, Andrew (2007-03-07). "To Settle Suit, Maker Agrees to Withdraw Growth Drug". The New York Times. ISSN 0362-4331. Retrieved 2020-02-06.
- "Ipsen buys Tercica for $404 million". www.bizjournals.com. Retrieved 2018-06-22.
External links
- Ipsen Biopharmaceuticals website
 | This biotechnology article is a stub. You can help Misplaced Pages by expanding it. |
 | This United States corporation or company article is a stub. You can help Misplaced Pages by expanding it. |
 | This article about a medical, pharmaceutical or biotechnological corporation or company is a stub. You can help Misplaced Pages by expanding it. |